Treatment

Ultomiris 300 mg/30 mL concentrate for solution for infusion clinical trials

4 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
This study is testing a new medicine called Ultomiris to see if it can help adults who get a serious side effect called TMA after a stem cell transplant. It's comparing Ultomiris to a dummy treatment.
For: Hematopoietic stem cell transplant-associated thrombotic microangiopathy
Germany · Poland · France
Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
This study is testing a new medicine, Ultomiris, for adults with kidney diseases called Lupus Nephritis or IgA Nephropathy. Doctors want to see if it reduces protein in their urine and helps their kidneys work better, compared to a dummy medicine.
For: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
Italy · Poland · Spain
Ongoing, recruitingTherapeutic confirmatory (Phase III)
ARTEMIS: RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
This study looks at a new medicine called Ultomiris to see if it can protect the kidneys of people with existing kidney problems who are having heart surgery. It aims to reduce serious kidney complications after the operation.
For: Prevention of cardiac surgery associated acute kidney injury
Italy · Germany · Poland
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to <18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
This study is testing a new medicine called Ultomiris for children and teenagers (from 1 month old to under 18) who get a serious condition called TMA after a stem cell transplant. It aims to see if Ultomiris helps treat TMA and improve their health.
For: Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)
Spain · France · Germany

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

ARTEMIS: RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study

A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to <18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)